35 search results for: asthma
The Risks of Associated Systemic and Atopic Comorbidities with AD
Dr. Paller explores the multifaceted impact of AD, highlighting its association with various comorbidities such as food allergies, asthma, allergic rhinitis, and mental health disorders.
EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?
Join Klaus Rabe, MD, PhD, FERS; Celeste Porsberg, MD, PhD; and Mario Castro, MD, MPH, for a symposium on airway remodeling in severe asthma patients.
Type 2 Asthma Learning Hub
Type 2 asthma is a common phenotype of asthma, characterized by key cytokines IL-4, IL-13, and IL-5, as well as elevated type 2 inflammatory biomarkers as FeNO, and eosinophils, or the need for maintenance OCS. Type 2 inflammation is evident in up to 88% of patients with severe asthma, representing a substantial portion of the disease burden associated with asthma. Explore the resources below better understand the role of type 2 inflammation in asthma.
Dr. Giorgio Canonica Regarding Multidisciplinary Approach
This video clip from the EAACI 2024 symposium highlights that a multidisciplinary approach is essential for the treatment of asthma.
ADVENT at ERS 2024
The ADVENT program will present four symposia sharing the latest science in asthma and COPD at the 2024 European Respiratory Society (ERS) Congress. Visit Booth #A4.02 to learn more about ADVENT.
Celeste Porsbjerg, MD, PhD
Professor of Severe Asthma, Bispebjerg Hospital Copenhagen, Denmark
Nicole Chase, MD
Associate Professor of Medicine, University of Minnesota; Physician Minneapolis VA Health Care System; Partner, St. Paul Allergy & Asthma, PA
ADVENT at EAACI PAAM 2025
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation processes underlying pediatric asthma, atopic dermatitis, and eosinophilic esophagitis.
Simon Couillard, MD, MSc
Professor Couillard is a respirologist and the Québec Lung Association Chair of Respiratory Research at the Université de Sherbrooke, Canada. He leads a team investigating ways to use biomarkers to predict and prevent asthma attacks and improve asthma management.
Njira Lugogo, MD
Dr. Lugogo is a Professor of Medicine in the Division of Pulmonary, Critical Care Medicine and is the Director of the Michigan Medicine Asthma Program. She is also the Program Director of INHALE, a statewide collaborative quality improvement program that focuses on improving the care of patients with asthma and COPD in Michigan.
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
